SCHEMBL5335839

SCHEMBL5335839

CC(C)CNc1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
BACE1 P56817 3/20 0.46
GPR119 Q8TDV5 2/20 0.46
NAMPT P43490 1/20 0.46
GLA P06280 1/20 0.46
TSHR P16473 1/20 0.46
MAPT P10636 1/20 0.46
GAA P10253 2/20 0.45
ALDH1A1 P00352 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SMARCA2 P51531 1/20 0.44
SMARCA4 P51532 1/20 0.44
PBRM1 Q86U86 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
CHRM2 P08172 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8985828 0.86 ACHE (0.50) ACHEBACE1GPR119NAMPTGLA
SCHEMBL5335893 0.84 MEN1 (0.69) MEN1KMT2AGLATSHRMAPT
SCHEMBL5337500 0.82 ALDH1A1 (0.67) MEN1KMT2ABACE1NAMPTGLA
SCHEMBL24641976 0.81 ACHE (0.53) ACHEBACE1GPR119NAMPTTSHR
SCHEMBL30017339 0.81 ACHE (0.53) ACHEBACE1GPR119NAMPTTSHR
SCHEMBL5333872 0.81 ACHE (0.48) ACHEBACE1GPR119NAMPTGLA
SCHEMBL5334602 0.81 BACE1 (0.46) MEN1KMT2ABACE1GPR119NAMPT
SCHEMBL25634800 0.80 BACE1 (0.49) ACHEBACE1GPR119NAMPTGLA
SCHEMBL17491558 0.80 NAMPT (0.52) MEN1KMT2ABACE1GPR119NAMPT
SCHEMBL5336322 0.80 ALDH1A1 (0.52) MEN1KMT2ABACE1NAMPTGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R ACHE 3483/4885MEN1 683/4885KMT2A 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.